June 19, 2024 09:22 AM EDT
Deals
Manufacturing

Sam­sung Bio and Bax­ter di­al up man­u­fac­tur­ing deal to $223M

Anna Brown

News Reporter

Bax­ter Health­care will pay Sam­sung Bi­o­log­ics an ex­tra $208 mil­lion to man­u­fac­ture cer­tain drug prod­ucts un­til the end of 2034 in a re­vised man­u­fac­tur­ing con­tract …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 11 win­ners: Big bets on AI, new fron­tiers in edit­ing, a neu­ro re­nais­sance and Chi­nese chem­istry

No­vo Nordisk to de­crease some in­sulin pen man­u­fac­tur­ing, tran­si­tion sup­ply

Cas­sa­va and its for­mer ex­ecs set­tle SEC charges for ‘mis­lead­ing’ Alzheimer’s drug da­ta

No­vo Nordisk CEO skep­ti­cal of PBM promis­es in Sen­ate hear­ing on weight loss drug prices

FDA ap­proves Dupix­ent in COPD, open­ing ‘next chap­ter’ for Sanofi and Re­gen­eron’s best­seller

sponsored

PD­Cs vs. AD­Cs: A New Fron­tier in Tar­get­ed Can­cer Ther­a­pies and the Po­ten­tial for De­vel­op­ment Part­ner­ships

A service from the Financial Times